First, RT enhances the generation of tumor-specific antibodies, possibly by amplifying the release of “tumor-specific” antigen pool for antigen presenting cells (APCs), such as, plasmacytoid dendritic cells (pDCs) and B-lymphocytes, while TLR9 agonists provide the activating signal for adaptive anti-tumoral immunity. Here, TLR9 is linked to neoplasm.